Most-Upgraded Stocks Most-Downgraded Stocks NASDAQ:SGEN Seagen - SGEN News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Seagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $203.02 +3.42 (+1.71%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$199.50▼$203.1950-Day Range$130.49▼$203.0252-Week Range$105.43▼$203.19Volume1.26 million shsAverage Volume2.02 million shsMarket Capitalization$37.92 billionP/E RatioN/ADividend YieldN/APrice Target$188.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Get Seagen News Delivered to You Automatically Sign up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address SGEN Media Mentions By Week SGEN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGEN News Sentiment▼0.340.61▲Average Medical News Sentiment SGEN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGEN Articles This Week▼126▲SGEN Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLion Street Advisors LLC Invests $238,000 in Seagen Inc. (NASDAQ:SGEN)marketbeat.com - March 29 at 6:58 AMWestern Financial Corp CA Takes $604,000 Position in Seagen Inc. (NASDAQ:SGEN)marketbeat.com - March 28 at 8:01 AMSeagen Inc. (NASDAQ:SGEN) Given Average Recommendation of "Hold" by Brokeragesmarketbeat.com - March 27 at 6:31 AMAssenagon Asset Management S.A. Sells 72,100 Shares of Seagen Inc. (NASDAQ:SGEN)marketbeat.com - March 27 at 4:46 AM3 Dividend Contenders to Buy Now for Long-Term Gains Later (SGEN)marketbeat.com - March 22 at 7:00 AMPfizer’s Latest Acquisition Strengthens the Case for PFE Stock (SGEN)marketbeat.com - March 15 at 12:00 PMSeagen (NASDAQ:SGEN) Now Covered by Analysts at StockNews.comamericanbankingnews.com - March 25 at 5:34 AMSeagen (NASDAQ:SGEN) Stock Rating Lowered by Berenberg Bankamericanbankingnews.com - March 24 at 7:56 AMSeagen (NASDAQ:SGEN) PT Lowered to $129.00americanbankingnews.com - March 23 at 2:52 AMTruist Financial Increases Seagen (NASDAQ:SGEN) Price Target to $229.00americanbankingnews.com - March 22 at 1:50 AMSeagen (NASDAQ:SGEN) Coverage Initiated at StockNews.comamericanbankingnews.com - March 20 at 8:38 AMSeagen Inc. (NASDAQ:SGEN) CMO Sells $1,998,100.00 in Stockamericanbankingnews.com - March 20 at 4:44 AMWhy Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?finance.yahoo.com - March 17 at 1:33 PMSeagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meetingfinance.yahoo.com - March 14 at 8:57 PMShareholder Alert: Ademi LLP investigates whether Seagen Inc. has obtained a Fair Price in its transaction with Pfizerbenzinga.com - March 14 at 5:30 AMSeagen Unusual Options Activity For March 13msn.com - March 14 at 5:30 AMBMO Capital downgrades Seagen (SGEN) to a Holdmarkets.businessinsider.com - March 14 at 5:30 AMPfizer Rolls the Dice on Seagen in $43 Billion Deal. The Risks It Faces.barrons.com - March 14 at 5:30 AMJMP Securities downgrades Seagen (SGEN) to a Holdmarkets.businessinsider.com - March 14 at 5:30 AMSEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGENbusinesswire.com - March 13 at 8:21 PMSGEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seagen Inc. Is Fair to Shareholdersbusinesswire.com - March 13 at 9:33 AMPfizer Invests $43 Billion to Battle Cancerfinance.yahoo.com - March 13 at 7:39 AMThe five-year returns have been impressive for Seagen (NASDAQ:SGEN) shareholders despite underlying losses increasingfinance.yahoo.com - March 5 at 8:58 AMEstimating The Fair Value Of Seagen Inc. (NASDAQ:SGEN)finance.yahoo.com - March 1 at 8:40 AMA Seagen Inc. (NASDAQ:SGEN) insider lowered their holding by 16% earlier this yearfinance.yahoo.com - February 25 at 10:45 AMSeagen Full Year 2022 Earnings: Beats Expectationsfinance.yahoo.com - February 17 at 10:41 AMWhy Seattle Genetics, Alkermes Are Currently Outperforming Their Peersfinance.yahoo.com - February 16 at 1:29 PMSeagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposiumfinance.yahoo.com - February 13 at 8:43 PMSeagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancerfinance.yahoo.com - January 19 at 5:13 PMSeagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023finance.yahoo.com - January 19 at 12:12 PMSeagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancerfinance.yahoo.com - December 20 at 7:40 AMAstellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancerfinance.yahoo.com - December 20 at 7:40 AMSeagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphomafinance.yahoo.com - December 12 at 4:47 PMSeagen Inc.'s (NASDAQ:SGEN) Intrinsic Value Is Potentially 98% Above Its Share Pricefinance.yahoo.com - December 7 at 5:46 PMSeagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meetingfinance.yahoo.com - December 1 at 10:08 AMInstitutional owners may consider drastic measures as Seagen Inc.'s (NASDAQ:SGEN) recent US$1.2b drop adds to long-term lossesfinance.yahoo.com - November 17 at 8:47 AMSeagen Names David R. Epstein as Chief Executive Officer and Directorfinance.yahoo.com - November 10 at 7:41 PMSeagen Appoints Sandra M. Swain, M.D., to Board of Directorsfinance.yahoo.com - November 10 at 7:41 PMSeagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meetingfinance.yahoo.com - November 10 at 7:41 PMSeagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphomafinance.yahoo.com - November 10 at 7:41 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Seagen (SGEN), Alnylam Pharma (ALNY) and BioMarin Pharmaceutical (BMRN)markets.businessinsider.com - October 31 at 1:16 AMSeagen Inc Q3 Loss decreases, but misses estimatesnasdaq.com - October 27 at 11:05 PMSeagen Inc. (SGEN) Q3 2022 Earnings Call Transcriptseekingalpha.com - October 27 at 11:05 PMSeagen Reports Third Quarter 2022 Financial Resultsfinance.yahoo.com - October 27 at 5:56 PMA Bearish Sign Appears On Seagen's Chartmsn.com - October 25 at 5:05 PMWhat 9 Analyst Ratings Have To Say About Seagenmsn.com - October 25 at 5:05 PMInvesting in Seagen (NASDAQ:SGEN) five years ago would have delivered you a 116% gainfinance.yahoo.com - October 19 at 5:38 PMLAVA Therapeutics: Assessing A Promising Innovator (NASDAQ:LVTX) - Seeking Alphaseekingalpha.com - October 18 at 8:12 AMWhat 8 Analyst Ratings Have To Say About Seagen - Seagen (NASDAQ:SGEN) - Benzingabenzinga.com - October 13 at 6:49 PMMorgan Stanley Maintains Overweight Rating for Seagen: Here's What You Need To Know - Seagen (NASDAQ:SGEN - Benzingabenzinga.com - October 13 at 1:49 PMNew Veeva Link Applications Give Clinical Teams Real-Time Intelligence to Optimize Site Selection and Trial Design - Yahoo Financefinance.yahoo.com - October 13 at 7:54 AMIs Seagen Stock a Buy Now? - The Motley Foolfool.com - October 12 at 4:23 PMIs Seagen Stock a Buy Now? - Nasdaqnasdaq.com - October 12 at 11:23 AMBMO Capital Upgrades Seagen: Here's What You Need To Know - Seagen (NASDAQ:SGEN) - Benzingabenzinga.com - October 11 at 2:12 PMSeagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022 - Business Wirebusinesswire.com - October 7 at 6:53 PMHere's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situationnasdaq.com - October 7 at 8:06 AM Get Seagen News Delivered to You Automatically Sign up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:SGEN) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.